Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1984 1
1985 2
1986 2
1988 3
1989 2
1990 4
1991 7
1992 4
1993 8
1994 7
1995 9
1996 7
1997 4
1998 7
1999 6
2000 5
2001 6
2002 2
2003 6
2004 7
2005 9
2006 4
2007 8
2008 8
2009 12
2010 13
2011 21
2012 12
2013 20
2014 32
2015 28
2016 23
2017 24
2018 42
2019 40
2020 28
2021 51
2022 45
2023 45
2024 36
2025 36
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

555 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean t ruckh (12 results)?
Primary Angiitis of the CNS: A Systematic Review and Meta-analysis.
Beuker C, Strunk D, Rawal R, Schmidt-Pogoda A, Werring N, Milles L, Ruck T, Wiendl H, Meuth S, Minnerup H, Minnerup J. Beuker C, et al. Neurol Neuroimmunol Neuroinflamm. 2021 Oct 18;8(6):e1093. doi: 10.1212/NXI.0000000000001093. Print 2021 Nov. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34663675 Free PMC article.
Effective use of BCMA-targeting bispecific T cell-engaging antibody in treatment-refractory LRP4(+) myasthenia gravis.
Schreiber S, Al-Dubai M, Vielhaber S, Lefterova L, Dietrich S, Ruck T, Meuth S, Walther D, Mougiakakos D. Schreiber S, et al. Mol Ther. 2025 Sep 3;33(9):4130-4134. doi: 10.1016/j.ymthe.2025.06.029. Epub 2025 Jun 17. Mol Ther. 2025. PMID: 40534130 Free article.
Teclistamab, a bispecific antibody targeting B cell maturation antigen (BCMA) and CD3, redirects T cells against plasma cells and is approved for multiple myeloma treatment. Increasing interest surrounds the use of T cell-based therapies in B cell-mediated autoimmun …
Teclistamab, a bispecific antibody targeting B cell maturation antigen (BCMA) and CD3, redirects T cells against plasma cells and is …
Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society.
Melzer N, Ruck T, Fuhr P, Gold R, Hohlfeld R, Marx A, Melms A, Tackenberg B, Schalke B, Schneider-Gold C, Zimprich F, Meuth SG, Wiendl H. Melzer N, et al. J Neurol. 2016 Aug;263(8):1473-94. doi: 10.1007/s00415-016-8045-z. Epub 2016 Feb 17. J Neurol. 2016. PMID: 26886206 Free PMC article. Review.
Impairment of central thymic and peripheral self-tolerance mechanisms in both cases is thought to favor an autoimmune CD4(+) T cell-mediated B cell activation and synthesis of pathogenic high-affinity autoantibodies of either the IgG1 and 3 or IgG4 subclass. ...
Impairment of central thymic and peripheral self-tolerance mechanisms in both cases is thought to favor an autoimmune CD4(+) T cell-m …
Metabolic and ruck performance effects of a novel, light-weight, energy-dense ketogenic bar.
Buga A, Crabtree CD, Stoner JT, Decker DD, Robinson BT, Kackley ML, Sapper TN, Buxton JD, D'Agostino DP, McClure TS, Berardi A, Cline S, Fleck T, Krout J, Newby D, Koutnik AP, Volek JS, Prins PJ. Buga A, et al. Exp Physiol. 2023 May;108(5):715-727. doi: 10.1113/EP091029. Epub 2023 Mar 13. Exp Physiol. 2023. PMID: 36915239 Free PMC article. Clinical Trial.

Neither bar influenced glycaemia. Lactate increased during the ruck independent of the condition (P < 0.0001). Thirst/fullness perceptions changed independent of the nutritional bar consumed. A novel KB nutritional bar produced equivalent TTE ruck results to the

…

Neither bar influenced glycaemia. Lactate increased during the ruck independent of the condition (P < 0.0001). Thirst/fullness per

…
TREK-king the blood-brain-barrier.
Bittner S, Ruck T, Fernández-Orth J, Meuth SG. Bittner S, et al. J Neuroimmune Pharmacol. 2014 Jun;9(3):293-301. doi: 10.1007/s11481-014-9530-8. Epub 2014 Feb 21. J Neuroimmune Pharmacol. 2014. PMID: 24557892 Review.
Olduvai's oldest Oldowan.
Stollhofen H, Stanistreet IG, Toth N, Schick KD, Rodríguez-Cintas A, Albert RM, Farrugia P, Njau JK, Pante MC, Herrmann EW, Ruck L, Bamford MK, Blumenschine RJ, Masao FT. Stollhofen H, et al. J Hum Evol. 2021 Jan;150:102910. doi: 10.1016/j.jhevol.2020.102910. Epub 2020 Nov 30. J Hum Evol. 2021. PMID: 33271475
CD19xCD3 T cell engager blinatumomab effective in refractory generalized myasthenic syndromes.
Ruck T, Huntemann N, Öztürk M, Schreiber S, Lichtenberg S, Masanneck L, Nelke C, Ben Moussa H, Ulrych T, Seifert M, Mougiakakos D, Dietrich S, Meuth SG. Ruck T, et al. Mol Ther. 2025 Sep 3;33(9):4135-4142. doi: 10.1016/j.ymthe.2025.06.042. Epub 2025 Jun 28. Mol Ther. 2025. PMID: 40583272 Free article.
In this case series, we report the first off-label use of the CD19xCD3 T cell engager blinatumomab in two patients with generalized myasthenia gravis (MG). ...This report underscores the potential of CD19xCD3 T cell engagers as a promising therapeutic approach in se …
In this case series, we report the first off-label use of the CD19xCD3 T cell engager blinatumomab in two patients with generalized m …
555 results